

Contents

1. Global Epidemiology of West Nile Virus

Lyle R. Petersen

1. Introduction	1
2. West Nile Virus in Africa, Asia, and Europe	4
2.1. Africa	4
2.2. Middle East, Russia, Asia, and Australia	5
2.3. Europe	6
3. West Nile Virus in the Americas	7
3.1. United States	7
3.1.1. Mosquitoes and Vertebrates	7
3.1.2. Human Incidence and Distribution	8
3.2. Canada	11
3.3. Latin America and the Caribbean	11
4. Clinical Epidemiology	12
4.1. Risk Factors Associated with Human Disease	12
4.2. Transmission Modes	14
5. Summary	16

2. West Nile Virus: Molecular Epidemiology and Diversity

Gregory D. Ebel and Laura D. Kramer

1. Overview of WNV Genetic Diversity at a Global Scale	25
2. Molecular Epidemiology of WNV in the Americas	27
2.1. Evidence for a Single Point Introduction	27
2.2. Genetic Conservation and Diversification During Colonization	28
2.3. Insights into WNV Population Dynamics	30
2.4. Sampling Bias and Methodological Issues:	
Impact on Conclusions	31
2.5. Implications for WNV Pathogenesis	33
3. Ecology and Phylogeny: WNV Adaptation	
in the Western Hemisphere	34
3.1. General Considerations	34
3.2. Adaptation to Mosquito Hosts	36
3.3. Adaptation to Avian Hosts	36
4. Evolutionary Mechanisms in West Nile Virus	37
5. Summary and Future Studies	38

3. Vector Biology and West Nile Virus

Carol D. Blair

1. Introduction: Importance of Vector Biology in West Nile Virus Ecology	45
2. Transmission of West Nile Virus	46
2.1. Natural Transmission Cycle	46
2.2. Vector Competence and Vectorial Capacity	47
2.3. Mosquitoes Involved in Transmission of WNV	49
2.4. Other Potential Arthropod Vectors	51
2.5. Role of Vectors in Overwintering	51
3. Genetics and Molecular Biology of Virus–Mosquito Interactions	53
3.1. Influence of Mosquito Genetics on WNV Transmission	53
3.2. Key Interaction: Infection of and Dissemination from the Midgut	53
3.3. Transmission by Bite: Mosquito Salivary Proteins	54
3.4. Potential Barriers to Infection: Mosquito Defense Mechanisms	55
3.5. Pathogenesis in Mosquito Tissues	58
3.6. Role of Virus Genetics in Vector Interactions	59
4. Control of WNV Disease: Interruption of the Transmission Cycle	60
5. Conclusion	61

4. Clinical Manifestations of Neurological Disease

J. David Beckham and Kenneth L. Tyler

1. Introduction	69
2. Epidemiology and Risk Factors for WNV Neuroinvasive Disease	70
3. Clinical Manifestations	72
3.1. West Nile Meningitis	74
3.2. West Nile Encephalitis	77
3.3. West Nile Acute Flaccid Paralysis	81
3.4. Other Clinical Manifestations	83
4. Outcomes and Prognoses	84
5. Therapy of West Nile Virus Infection	86

5. Molecular Biology of West Nile Virus

Margo A. Brinton

1. Introduction	97
2. Virus Classification	98
3. Genome RNA	98
4. Virion Morphology and Proteins	99
5. WNV Replication Cycle	101
6. Viral Nonstructural Proteins	104
7. In Vitro Polymerase Assays	112
8. Conserved Viral RNA Terminal Structures and Sequences	113
8.1. Conserved Sequences	113
8.2. Secondary Structures	115

8.3. Tertiary Structures	116
9. Host Cell Proteins Interact with the WNV 3' Terminal SLs and Facilitate RNA Synthesis	116
9.1. Cellular Proteins Bind to the 3'(+) SL RNA	117
9.2. Cellular Proteins Bind to the 3'(-) SL	119
9.3. Virus Interactions with the Host Cell.....	121
9.4. Host Genetic Resistance to Flavivirus-Induced Disease.....	122
9.5. Virulence Determinants.....	123
10. Conclusions.....	124

6. Virulence of West Nile Virus in Different Animal Hosts

David W.C. Beasley and Alan D.T. Barrett

1. Introduction	137
2. Classification of West Nile Virus Strains: Antigenic and Nucleotide Sequence Diversity	138
3. WNV: Natural Hosts, Animal Models and Disease.....	140
3.1. WNV Disease in Humans	140
3.2. Nonhuman Primates.....	142
3.3. Avians.....	142
3.4. Equines.....	143
3.5. Chipmunks, Rabbits, and Tree Squirrels	144
3.6. Small Animal Models: Mice and Hamsters.....	144
4. Molecular Determinants of Natural Virulence Variations Between WNV Strains.....	145
4.1. Contribution of Individual Viral-Encoded Proteins to WNV Virulence	145
4.2. Comparative Studies of WNV Virulence in Mouse and Hamster Models	146
4.3. Emergence and Characterization of Attenuated WNV Variants in the Americas.....	147
4.4. Determinants of Virulence in Avians	148
5. Summary.....	149

7. Innate Immune Response and Mechanisms of Interferon Antagonism Against West Nile Virus

Jared D. Evans and Christoph Seeger

1. Introduction	155
2. Recognition of WNV by Cellular Sensors: Activation of the First Wave of the Innate Immune Response.....	155
3. INF- α and IFN Stimulated Genes (ISGs) Are Essential for Survival of WNV Infections	159
4. Effectors of the IFN Response	160
5. Viral Antagonism of the IFN Response	162
6. What Is the Mechanism Responsible for this Inhibition of the IFN Response?.....	164
7. Implications for Natural Infections in Humans.....	164

8. Innate Immune Responses to West Nile Virus Infection

Alvaro Arjona and Erol Fikrig

1. Introduction	169
2. Sensing WNV Infection: Role of Pattern-Recognition Receptors	170
2.1. Toll-Like Receptors.....	172
2.2. RNA Helicases	174
2.3. Nonconventional PRRs.....	175
3. Role of Innate Immune Cells in WNV Infection	175
3.1. Macrophages	175
3.2. Dendritic Cells.....	176
3.3. γ/δ T Cells	177
3.4. NK Cells.....	178
4. Cytokines Involved in Innate Responses to WNV Infection.....	179
4.1. Macrophage Migration Inhibitory Factor.....	179
4.2. IFN- γ	181
4.3. Other Inflammatory Cytokines.....	181
5. Concluding Remarks.....	182

9. Mechanisms of Complement Regulation of Infection by Flaviviruses

Erin Mehlhop and Michael S. Diamond

1. Introduction	189
2. The Complement System.....	190
2.1. Complement Activation.....	191
2.1.1. Classical Pathway.....	192
2.1.2. Lectin Pathway.....	194
2.1.3. Alternative Pathway	194
2.1.4. Terminal Pathway	195
2.2. Complement Receptors Link Activation to Adaptive Immune Responses	196
2.3. Regulators of Complement Activation	198
3. Complement Regulation of Flavivirus Infection	199
3.1. Flavivirus Infection Activates Complement	200
3.2. Complement Augments Antibody-Mediated Neutralization of Flaviviruses.....	200
3.3. C1q Restricts Antibody-Dependent Enhancement of Flaviviruses	201
3.4. Complement C3 Enhances Flavivirus Infection via CR3	202
3.5. Complement Stimulates Adaptive Immunity to Flavivirus Infections	202
4. Immune Evasion of Complement by Flaviviruses	204
5. Concluding Remarks.....	205

10. Antibody-Mediated Neutralization of West Nile Virus: Factors that Govern Neutralization Potency

Christiane A. Jost and Theodore C. Pierson

1. Introduction	219
2. Flavivirus Virion Structure	220
3. The Structure of the Envelope Protein and Epitopes Recognized by Neutralizing Antibodies	222
4. The Stoichiometry of Flavivirus Neutralization	225
4.1. Epitope Accessibility Governs the Neutralization Potency of Antibodies	225
4.2. The Stoichiometry of WNV Neutralization	227
5. Factors that Modulate Antibody Potency	228
5.1. Impact of Virion Maturation of Antibody-Mediated Neutralization	229
5.2. Complement Augments the Neutralization Potency of Antibodies	232
6. Mechanisms of Neutralization	232
7. Antibody Dependent Enhancement of Infection	234
7.1. The Stoichiometry of ADE	236
7.2. Mechanisms of ADE	236
8. Implications for Vaccine Development	237

11. Structural Basis of Antibody Protection Against West Nile Virus

Richard J. Kuhn

1. Introduction	249
2. Structure of West Nile Virus	250
2.1. The Viral Proteins	250
2.2. The Flavivirus Virion	252
2.3. Immature WNV Particles	253
3. Structural Basis of West Nile Virus Neutralization	254
3.1. WNV Antibody Neutralization	254
3.2. Structure of the E16 Fab–Domain III Complex	255
3.3. Structure of E16 Complexed with Virus	257
3.4. Implications for Function	258
4. Mechanisms of Action of Other Antibodies	260
4.1. Neutralization of Dengue Virus by 1A1D-2	260
5. Structural Insights into Antibody-Mediated Flavivirus Neutralization	261

12. Molecular Mechanisms of Flaviviral Membrane Fusion

Yorgo Modis and Vinod Nayak

1. Introduction	266
2. Overall Architecture of Flaviviral Membrane Fusion Proteins	267
3. Maturation and Priming of Fusion-Competent Virions	270
4. The Fusogenic Conformational Rearrangement	272
5. The Flaviviral Fusion Loop	273

6. Mechanism of Flaviviral Membrane Fusion	276
7. Strategies for Fusion Inhibition.....	279

13. CD4⁺ and CD8⁺ T-Cell Immune Responses in West Nile Virus Infection

Mario Lobigs, Arno Müllbacher, and Matthias Regner

1. Role of T Cells in Viral Infection: An Overview	287
2. WNV-Immune CD4 ⁺ and CD8 ⁺ T-Cell Responses, In Vitro	289
2.1. The CD4 ⁺ T-Cell Response	289
2.2. The CD8 ⁺ T-Cell Response	290
3. Role of CD4 ⁺ T Cells in Recovery from WNV Infection	292
4. Role of CD8 ⁺ T Cells in Recovery from WNV Infection	294
5. Effector Mechanisms of WNV-Immune T Cells:	
Cytokines and Cytolytic Pathways	295
5.1. Cytokines.....	295
5.2. Cytotoxicity	296
6. T-Cell Trafficking into the CNS	299
7. T-Cell-Mediated CNS Pathology in WNV Infection	301

14. Enhanced Antigen Processing or Immune Evasion? West Nile Virus and the Induction of Immune Recognition Molecules

*Nicholas J.C. King, Ariane Davison, Daniel R. Getts,
David Ping Lu, Meghann Teague Getts, Amanda Yeung,
James K. Peterson, and Alison M. Kesson*

1. Introduction	310
2. Cell Surface Molecule Upregulation by West Nile Virus	311
2.1. West Nile Virus-Induced Cell Surface MHC Expression Is Functional	311
2.2. Type I Interferon and the Cell Cycle in the Responses to West Nile Virus.....	313
2.3. West Nile Virus-Induced Increase in ICAM-1 Expression	313
2.4. Increased Gene Transcription of WNV-Induced Immune Molecules Is Interferon Independent	314
3. Intracellular Responses to West Nile Virus.....	314
3.1. Increased Immune Molecule Expression Is Mediated by NF- κ B	314
3.2. NF- κ B Activation Is Independent of IFN and TNF	315
3.3. Involvement of Interferon Regulatory Factor-1 In WNV Responses.....	316
4. Decoy Hypothesis	316
4.1. Cell Surface Molecule Concentration and the Immunological Synapse	316
4.2. Recruitment of Low Affinity T Cells	317
4.3. Involvement of Cell Cycle: Divide and Conquer.....	319
4.4. Disease Resolution or Progression to Autoimmune Disease?	319
5. Mathematical Modelling of WNV Immune Responses	320

6. Modelling Impact of WNV-Induced MHC Increases In Vivo:	
Embryonic Infection	322
6.1. Immunological Silence and the Developing Embryo.....	322
6.2. Model of Embryonic Infection	323
6.3. Exogenous Infection in Pregnancy.....	324
7. Initiation of Immunity: Impact on Ag Presentation	325
7.1. Dendritic Cells and Virus Infection.....	325
7.2. The Langerhans Cell Response to West Nile Virus Infection	326
7.3. Novel Skin Model.....	328
7.4. Dendritic Cells in the CNS	330
8. Conclusions.....	332

15. Chemokines and Clearance of West Nile Virus Infection

Robyn S. Klein

1. Introduction	342
2. Chemokines and Viral Infections	343
2.1. Chemokines Participate in Innate and Adaptive Immune	
Responses During WNV Infection.....	345
2.2. WNV-Mediated Regulation of Chemokine Expression.....	347
2.3. Chemokines Shape Immune Responses	
to WNV Infection Within the CNS	349
3. Chemokine Studies in Human Cases of Flavivirus Encephalitis.....	352
4. Conclusions.....	353

16. Persistence of West Nile Virus Infection in Vertebrates

Robert B. Tesh and Shu-Yuan Xiao

1. Introduction	361
2. WNV Persistent Infection in Nonhuman Primates.....	362
3. WNV Persistent Infection in Hamsters.....	363
4. Serial Passage of WNV in Hamster Urine.....	365
5. Genetic Changes Associated with Persistent Infection.....	367
6. Phenotypic Changes Associated with Persistent Infection	369
7. Evidence for Persistent Infection with Other Flaviviruses.....	372
8. Summary and Speculation.....	373

17. West Nile Virus Infection of the Central Nervous System

Melanie A. Samuel and Michael S. Diamond

1. Introduction	379
2. Clinical Features of WNV Neuroinvasive Disease.....	380
2.1. WNV Meningitis	382
2.2. WNV Encephalitis.....	382
2.3. Acute Flaccid Paralysis.....	383
2.4. Laboratory Findings and Diagnosis	384
2.5. Prognosis and Outcome.....	384
2.6. Potential Therapies	385

3. Pathogenesis of WNV in the CNS.....	385
3.1. Neuropathology.....	385
3.2. Mechanisms of CNS Injury and Disease	387
4. WNV Entry into the CNS.....	388
5. CNS Immune Responses to WNV.....	390
5.1. Innate Immune Responses in the CNS.....	390
5.2. Adaptive Immune Responses in the CNS.....	391
6. Future Perspectives	393

18. The Human Antibody Response Against WNV

Mark Throsby, Jaap Goudsmit, and John de Kruif

1. Introduction.....	401
2. Natural Infections in Humans.....	402
3. Serology	403
4. Antibody Repertoire Analysis	405
5. Epitope Mapping	407
6. Conclusion	411

19. Antibody Protection and Therapy for West Nile Virus Infections

John T. Roehrig

1. Introduction.....	417
2. The Role of the E Protein in Antiflaviviral Immunity.....	418
3. Using Small Animal Models of Infection to Define Antibody-Mediated Protection and Therapy.....	419
4. Previous Use of Human Antibody for Prophylaxis and Therapy for Flaviviral Infections	420
5. MAbs as Human Therapeutics.....	421
6. Conclusion	422

20. Vaccine Development Against West Nile Virus

Alexander, A. Khromykh, David, C. Chang, and Roy A. Hall

1. Background.....	428
2. Inactivated Vaccines	429
3. Recombinant Subunit Vaccines	429
4. Viral-Vectored WNV Vaccines	430
4.1. Canarypox Vector.....	430
4.2. Measles Virus Vector	431
4.3. Lentiviral Vector	431
4.4. Equine Herpesvirus Vector	432
5. Live Attenuated Vaccines	432
5.1. Attenuated WNV Isolates.....	433
5.2. Kunjin Virus	433
6. Chimeric Viruses	435
6.1. ChimeriVax-WN.....	437
6.2. WNV/DEN4 Chimera	438
6.3. DEN2/WNV Chimera	439

7. Conventional Non-infectious DNA Vaccines	440
8. Novel Nucleic Acid-Based Approaches for WNV	
Vaccine Development	442
8.1. Infectious Nucleic Acid Vaccines	442
8.2. Non-infectious, Replicating Vaccines	444
8.3. RNA-Based Capsid-Deleted Vaccines.....	444
8.4. VLP-Based Capsid-Deleted Vaccines	445
8.5. DNA-Based Capsid-Deleted Vaccine.....	445
8.6. Replicating DNA Vaccine Producing Single Round	
Infectious Particles.....	446
9. Conclusions and Future Directions	446

21. Novel Therapeutics Against West Nile Virus

Pei-Yong Shi

1. Introduction	453
2. Strategies for the Identification of Novel Small	
Molecular Inhibitors	454
2.1. Rational Design	454
2.2. Biochemical Enzyme-Based Screening	456
2.3. Genetic Cell-Based Screening	457
3. Current WNV Inhibitors.....	460
3.1. Macromolecular Inhibitors.....	460
3.1.1. Antibody	460
3.1.2. Interferon	461
3.1.3. Small Peptides	461
3.1.4. Antisense Phosphorodiamidate Morpholino Oligomers.....	462
3.1.5. siRNA.....	462
3.2. Small Molecular Inhibitors.....	463
3.2.1. Inhibitors of Nucleoside Triphosphate Synthesis	463
3.2.2. NTPase/Helicase Inhibitors.....	464
3.2.3. Protease Inhibitors	464
3.2.4. Host Glucosidase Inhibitors.....	465
3.2.5. Other Small Molecular Inhibitors	466
4. New Antiviral Targets and Challenges on Antiviral Development	467

Index	475
--------------------	------------